VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Vivos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.13+0.00 (+2.90%)
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$8.14M
$7.77M due within a year
Net debt
$6.36M
After $1.77M of cash
Implied interest rate
27.94%
FY2025 interest ÷ average debt
Interest coverage
-14.2×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Vivos Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.